Connecta Therapeutics
A biotechnology company developing new treatments for unmet CNS medical needs.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
€2.5m | Grant | ||
| Total Funding | 000k | ||
| EUR | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | 70 % | (29 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | 3 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | 2 % | 1 % | (7 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Connecta Therapeutics is a biopharmaceutical startup that focuses on the discovery and development of new treatments for Central Nervous System (CNS) disorders. The company is dedicated to addressing unmet medical needs, particularly in the field of inherited intellectual disabilities. Their primary target market includes patients suffering from CNS disorders and their families, with a specific focus on Fragile X Syndrome (FXS), the most common form of inherited intellectual disability that currently lacks a specific treatment.
The company's business model revolves around the research, development, and eventual commercialization of innovative therapies. Their primary product in development is CTH120, a drug currently in Phase IIa clinical trials. This phase will assess the efficacy of CTH120 as a potential treatment for adults with FXS.
Connecta Therapeutics generates revenue through the successful development and subsequent sale of their pharmaceutical products. The company's first Phase I clinical trial of CTH120 has been administered to the first batch of healthy volunteers at the Hospital del Mar – Hospital del Mar Research Institute in Barcelona. The study aims to recruit 68 healthy individuals, both women and men aged between 18 and 55.
Keywords: Biopharmaceutical, Central Nervous System (CNS), Fragile X Syndrome (FXS), Clinical Trials, Drug Development, Innovative Therapies, Intellectual Disabilities, CTH120, Medical Research, Pharmaceutical Sales.